Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details) - Vaxcyte, Inc. - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Deferred Royalty Obligation [Line Items] | ||
| Liability related to sale of future Vaxcyte royalties - beginning balance | $ 180,809 | $ 149,114 |
| Non-cash interest expense associated with the sale of future Vaxcyte royalties | 38,208 | 31,070 |
| Amortization of issuance costs | 519 | 625 |
| Liability related to the sale of future Vaxcyte royalties - ending balance | $ 219,536 | $ 180,809 |